Skip to main content
. 2011 Sep 9;2:27. doi: 10.3389/fendo.2011.00027

Figure 2.

Figure 2

Sunitinib inhibits proliferation of ACC cell lines in a dose-dependent manner. (A) NCI-H295 cells were counted after 2, 4, and 6 days of incubation with up to 5 μM sunitinib. After 2 days of incubation, we observed a dose-dependent reduction of viable cells to 99.6 ± 7.5% (0.1 μM sunitinib, n.s.), 84 ± 6% (1 μM, n.s.), 66 ± 10%* (5 μM) as compared to untreated control incubations (100 ± 5.2%). (B) After 5 days of incubation, viable cells were determined using the MTT assay. Viable NCI-H295 cells were reduced to 98 ± 8% (0.1 μM, n.s.), 91 ± 4%** (1 μM), and 80 ± 3%** (5 μM) compared to controls (100 ± 8%). Similarly, SW13 vital cells declined to 96 ± 7% (0.1 μM), 90.0 ± 9.2%** (1 μM), and 62 ± 6%** (5 μM) compared to control (100 ± 9%). *p < 0.05, **p < 0.01 compared to control.